嵌合抗原受体T细胞疗法在膀胱癌中的研究进展

doi:10.3969/j.issn.1006-5725.2025.22.005

Abstract

Abstract:

Bladder cancer （BCa） is a common malignant tumor of the urinary system， and its conventional treatment methods have many limitations. Chimeric antigen receptor T cell （CAR-T） therapy， as an emerging immunotherapy method， has achieved significant success in hematological malignancies and has brought new hope for the treatment of solid tumors. This article reviews the research progress of CAR-T cell therapy in the treatment of BCa， including the basic structure of CAR-T cells， potential therapeutic targets in bladder cancer， current challenges and corresponding strategies.

Key words: chimeric antigen receptor T cell, bladder cancer, immunotherapy

CLC Number:

R735

Zongjian HU,Shun WAN,Jianwei YANG,Li WANG,Siyu CHEN,Li YANG. Research progress of CAR⁃T cell therapy in bladder cancer[J]. The Journal of Practical Medicine, 2025, 41(22): 3496-3500.

References 50

[1]	BRAY F， LAVERSANNE M， SUNG H， et al. Global cancer statistics 2022： GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin， 2024， 74（3）： 229-263. doi:10.3322/caac.21834 doi: 10.3322/caac.21834
[2]	COMPÉRAT E， AMIN M B， CATHOMAS R， et al. Current best practice for bladder cancer： A narrative review of diagnostics and treatments［J］. Lancet， 2022， 400（10364）： 1712-1721. doi:10.1016/s0140-6736(22)01188-6 doi: 10.1016/s0140-6736(22)01188-6
[3]	任翔，曾晓勇. 2024年膀胱癌诊治进展［J］. 泌尿外科杂志（电子版）， 2025， 17（1）： 22-30.
[4]	杨龙雨禾，王跃强，招云亮，等. 人工智能辅助临床决策在泌尿系肿瘤的应用进展［J］. 中华腔镜泌尿外科杂志（电子版），2024，18（2）：178-182.
[5]	WEINBERG M S， ZAFAR A， MAGDAMO C， et al. Association of BCG Vaccine Treatment With Death and Dementia in Patients With Non-Muscle-Invasive Bladder Cancer［J］. JAMA Netw Open， 2023， 6（5）： e2314336. doi:10.1001/jamanetworkopen.2023.14336 doi: 10.1001/jamanetworkopen.2023.14336
[6]	SEIDL C. Targets for Therapy of Bladder Cancer［J］. Semin Nucl Med， 2020， 50（2）： 162-170. doi:10.1053/j.semnuclmed.2020.02.006 doi: 10.1053/j.semnuclmed.2020.02.006
[7]	ELLIS G I， SHEPPARD N C， RILEY J L. Genetic engineering of T cells for immunotherapy［J］. Nat Rev Genet， 2021， 22（7）： 427-447. doi:10.1038/s41576-021-00329-9 doi: 10.1038/s41576-021-00329-9
[8]	KUMAR A R， DEVAN A R， NAIR B， et al. Harnessing the immune system against cancer： Current immunotherapy approaches and therapeutic targets［J］. Mol Biol Rep， 2021， 48（12）： 8075-8095. doi:10.1007/s11033-021-06752-9 doi: 10.1007/s11033-021-06752-9
[9]	DABAS P， DANDA A. Revolutionizing cancer treatment： A comprehensive review of CAR-T cell therapy［J］. Med Oncol， 2023， 40（9）： 275. doi:10.1007/s12032-023-02146-y doi: 10.1007/s12032-023-02146-y
[10]	ABBASI S， TOTMAJ M A， ABBASI M， et al. Chimeric antigen receptor T （CAR-T） cells： Novel cell therapy for hematological malignancies［J］. Cancer Med， 2023， 12（7）： 7844-7858. doi:10.1002/cam4.5551 doi: 10.1002/cam4.5551
[11]	董蒨蒨，李玉淼. CAR-T在血液类恶性肿瘤中的研究进展［J］. 中国生物工程杂志， 2023， 43（6）： 43-53.
[12]	孙昭晨，蒋君妍，陈一天. CAR-T细胞在结直肠癌治疗方面的研究进展［J］. 实用医学杂志， 2024， 40（18）： 2640-2646.
[13]	田静，张之勇，白天凯，等. 嵌合抗原受体T细胞免疫疗法治疗胰腺癌的研究进展［J］. 实用医学杂志， 2022， 38（4）： 516-521.
[14]	GALLEGO-VALLE J， PÉREZ-FERNÁNDEZ V A， ROSALES-MAGALLARES J， et al. High specificity of engineered T cells with third generation CAR （CD28-4-1BB-CD3-ζ） based on biotin-bound monomeric streptavidin for potential tumor immunotherapy［J］. Front Immunol， 2024， 15： 1448752. doi:10.3389/fimmu.2024.1448752 doi: 10.3389/fimmu.2024.1448752
[15]	THISTLETHWAITE F C， GILHAM D E， GUEST R D， et al. The clinical efficacy of first-generation carcinoembryonic antigen （CEACAM5）-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity［J］. Cancer Immunol Immunother， 2017， 66（11）： 1425-1436. doi:10.1007/s00262-017-2034-7 doi: 10.1007/s00262-017-2034-7
[16]	DEL BUFALO F， BECILLI M， ROSIGNOLI C， et al. Allogeneic， donor-derived， second-generation， CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL［J］. Blood， 2023， 142（2）： 146-157.
[17]	FLUGEL C L， MAJZNER R G， KRENCIUTE G， et al. Overcoming on-target， off-tumour toxicity of CAR T cell therapy for solid tumours［J］. Nat Rev Clin Oncol， 2023， 20（1）： 49-62. doi:10.1038/s41571-022-00704-3 doi: 10.1038/s41571-022-00704-3
[18]	TANG L， PAN S， WEI X， et al. Arming CAR-T cells with cytokines and more： Innovations in the fourth-generation CAR-T development［J］. Mol Ther， 2023， 31（11）： 3146-3162. doi:10.1016/j.ymthe.2023.09.021 doi: 10.1016/j.ymthe.2023.09.021
[19]	ADACHI Y， TERAKURA S， OSAKI M， et al. Cullin-5 deficiency promotes chimeric antigen receptor T cell effector functions potentially via the modulation of JAK/STAT signaling pathway［J］. Nat Commun， 2024， 15（1）： 10376. doi:10.1038/s41467-024-54794-x doi: 10.1038/s41467-024-54794-x
[20]	CHEN W， ZHANG Z， ZHANG S， et al. MUC1： Structure， Function， and Clinic Application in Epithelial Cancers［J］. Int J Mol Sci， 2021， 22（12）： 6567. doi:10.3390/ijms22126567 doi: 10.3390/ijms22126567
[21]	QING L， LI Q， YANG Y， et al. Hypoxia-mediated attenuation of EGLN2 inhibition of the NF-κB signaling pathway leads to the formation of a loop between HIF-1α and MUC1-C promoting chemoresistance in bladder cancer［J］. Mol Carcinog， 2024， 63（7）： 1303-1318. doi:10.1002/mc.23725 doi: 10.1002/mc.23725
[22]	YU L， LI Z， MEI H， et al. Patient‐derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR‐T cells in vitro［J］. Clin Transl Immunology， 2021， 10（2）： e1248. doi:10.1002/cti2.1248 doi: 10.1002/cti2.1248
[23]	KANG X， LI R， LI X， et al. EGFR mutations and abnormal trafficking in cancers［J］. Mol Biol Rep， 2024， 51（1）： 924. doi:10.1007/s11033-024-09865-z doi: 10.1007/s11033-024-09865-z
[24]	OZSAGIR Y O， OZSAGIR E， DIL E， et al. Prognostic impact of EGFR expression and immunohistochemistry-based “molecular classification” in bladder cancer［J］. Ann Diagn Pathol， 2024， 73： 152380. doi:10.1016/j.anndiagpath.2024.152380 doi: 10.1016/j.anndiagpath.2024.152380
[25]	PARRIOTT G， DEAL K， CREAN S， et al. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer［J］. Immunology， 2020， 160（3）： 280-294. doi:10.1111/imm.13187 doi: 10.1111/imm.13187
[26]	MASUBUCHI T， CHEN L， MARCEL N， et al. Functional differences between rodent and human PD-1 linked to evolutionary divergence［J］. Sci Immunol， 2025， 10（103）： eads6295. doi:10.1126/sciimmunol.ads6295 doi: 10.1126/sciimmunol.ads6295
[27]	DARWISH I A， ALAHMAD W， VINOTH R. Novel ultrasensitive automated kinetic exclusion assay for measurement of plasma levels of soluble PD-L1， the predictive and prognostic biomarker in cancer patients treated with immune checkpoint inhibitors［J］. Heliyon， 2024， 10（10）： e31317. doi:10.1016/j.heliyon.2024.e31317 doi: 10.1016/j.heliyon.2024.e31317
[28]	XU X， XIE T， ZHOU M， et al. Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation［J］. Nat Commun， 2024， 15（1）： 4237. doi:10.1038/s41467-024-48597-3 doi: 10.1038/s41467-024-48597-3
[29]	DING M， LIN J， QIN C， et al. Novel CAR‐T Cells Specifically Targeting SIA‐CIgG Demonstrate Effective Antitumor Efficacy in Bladder Cancer［J］. Adv Sci （Weinh）， 2024， 11（40）： 2400156. doi:10.1002/advs.202400156 doi: 10.1002/advs.202400156
[30]	LOBO N， SHARIAT S F， GUO C C， et al. What Is the Significance of Variant Histology in Urothelial Carcinoma？［J］. Eur Urol Focus， 2020， 6（4）： 653-663. doi:10.1016/j.euf.2019.09.003 doi: 10.1016/j.euf.2019.09.003
[31]	HUMPHREY P A， MOCH H， CUBILLA A L， et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B： Prostate and Bladder Tumours［J］. Eur Urol， 2016， 70（1）： 106-119. doi:10.1016/j.eururo.2016.02.028 doi: 10.1016/j.eururo.2016.02.028
[32]	CAO R， WANG G， QIAN K， et al. TM4SF1 regulates apoptosis， cell cycle and ROS metabolism via the PPARγ-SIRT1 feedback loop in human bladder cancer cells［J］. Cancer Lett， 2018， 414： 278-293. doi:10.1016/j.canlet.2017.11.015 doi: 10.1016/j.canlet.2017.11.015
[33]	YANG H， SONG H， YIP E， et al. Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression［J］. Nat Commun， 2025， 16（1）： 5312. doi:10.1038/s41467-025-59888-8 doi: 10.1038/s41467-025-59888-8
[34]	HOIMES C J， FLAIG T W， MILOWSKY M I， et al. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer［J］. J Clin Oncol， 2023， 41（1）： 22-31. doi:10.1200/jco.22.01643 doi: 10.1200/jco.22.01643
[35]	LU X， CHENG L， YANG C， et al. Crosstalk between bladder cancer and the tumor microenvironment： Molecular mechanisms and targeted therapy［J］. Innov Med， 2024， 2（4）： 100094. doi:10.59717/j.xinn-med.2024.100094 doi: 10.59717/j.xinn-med.2024.100094
[36]	卫阳兵，闫鹏宇，杨晓峰. 肿瘤微环境在膀胱癌发生发展中的作用机制［J］. 生命的化学， 2022， 42（9）： 1665-1671.
[37]	MARDIANA S， SOLOMON B J， DARCY P K， et al. Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression［J］. Sci Transl Med， 2019， 11（495）： eaaw2293. doi:10.1126/scitranslmed.aaw2293 doi: 10.1126/scitranslmed.aaw2293
[38]	RIVIÈRE I， SADELAIN M. Chimeric Antigen Receptors： A Cell and Gene Therapy Perspective［J］. Molecular Therapy， 2017， 25（5）： 1117-1124. doi:10.1016/j.ymthe.2017.03.034 doi: 10.1016/j.ymthe.2017.03.034
[39]	TANG N， CHENG C， ZHANG X， et al. TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors［J］. JCI Insight， 2020， 5（4）： e133977. doi:10.1172/jci.insight.133977 doi: 10.1172/jci.insight.133977
[40]	SHIMABUKURO-VORNHAGEN A， BÖLL B， SCHELLONGOWSKI P， et al. Critical care management of chimeric antigen receptor T-cell therapy recipients［J］. CA Cancer J Clin， 2022， 72（1）： 78-93. doi:10.3322/caac.21702 doi: 10.3322/caac.21702
[41]	MORRIS E C， NEELAPU S S， GIAVRIDIS T， et al. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy［J］. Nat Rev Immunol， 2022， 22（2）： 85-96. doi:10.1038/s41577-021-00547-6 doi: 10.1038/s41577-021-00547-6
[42]	STERNER R C， STERNER R M. CAR-T cell therapy： Current limitations and potential strategies［J］. Blood Cancer J， 2021， 11（4）： 69. doi:10.1038/s41408-021-00459-7 doi: 10.1038/s41408-021-00459-7
[43]	XIA X， YANG Z， LU Q， et al. Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy［J］. Mol Cancer， 2024， 23： 175. doi:10.1186/s12943-024-02079-8 doi: 10.1186/s12943-024-02079-8
[44]	SANTOMASSO B D， PARK J H， SALLOUM D， et al. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia［J］. Cancer Discov， 2018， 8（8）： 958-971. doi:10.1158/2159-8290.cd-17-1319 doi: 10.1158/2159-8290.cd-17-1319
[45]	CHEN X， LI P， TIAN B， et al. Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors［J］. Front Immunol， 2022， 13： 1079181. doi:10.3389/fimmu.2022.1079181 doi: 10.3389/fimmu.2022.1079181
[46]	LE R Q， LI L， YUAN W， et al. FDA Approval Summary： Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome［J］. Oncologist， 2018， 23（8）： 943-947. doi:10.1634/theoncologist.2018-0028 doi: 10.1634/theoncologist.2018-0028
[47]	PARK J H， NATH K， DEVLIN S M， et al. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma： Phase 2 trial interim results［J］. Nat Med， 2023， 29（7）： 1710-1717. doi:10.1038/s41591-023-02404-6 doi: 10.1038/s41591-023-02404-6
[48]	FLUGEL C L， MAJZNER R G， KRENCIUTE G， et al. Overcoming on-target， off-tumour toxicity of CAR T cell therapy for solid tumours［J］. Nat Rev Clin Oncol， 2023， 20（1）： 49-62. doi:10.1038/s41571-022-00704-3 doi: 10.1038/s41571-022-00704-3
[49]	TOKAREW N， OGONEK J， ENDRES S， et al. Teaching an old dog new tricks： Next-generation CAR T cells［J］. Br J Cancer， 2019， 120（1）： 26-37. doi:10.1038/s41416-018-0325-1 doi: 10.1038/s41416-018-0325-1
[50]	WANG H， WU Z， CUI D， et al. Triple knockdown of CD11a， CD49d， and PSGL1 in T cells reduces CAR-T cell toxicity but preserves activity against solid tumors in mice［J］. Sci Transl Med， 2025， 17（782）： eadl6432. doi:10.1126/scitranslmed.adl6432 doi: 10.1126/scitranslmed.adl6432

Research progress of CAR⁃T cell therapy in bladder cancer

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 50

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhicong LIU,Daiyin LIU,Juntian LONG,Chixing CHENG,Jian HUANG. Exosomal lncRNA CIAT1 promotes collective invasion of bladder cancer [J]. The Journal of Practical Medicine, 2025, 41(9): 1299-1308.
[2]	Daiyin LIU,Qiuyan LI,Changhao. CHEN. CircMYCBP2 enhances the formation of lymphovascular invasion of bladder cancer [J]. The Journal of Practical Medicine, 2025, 41(8): 1139-1148.
[3]	Hang LI,Xiaomei YANG,Wen LYU,Huimin CHEN,Rui. XU. Three⁃year evaluation of the efficacy and safety of chronotherapy in dual⁃allergen subcutaneous immunotherapy [J]. The Journal of Practical Medicine, 2025, 41(21): 3405-3411.
[4]	Qiang FU,Zhongqi LU,Ying CHANG,Tiefeng JIN,Meihua. ZHANG. Research progress on the antitumor effects of immune checkpoint inhibitors [J]. The Journal of Practical Medicine, 2025, 41(2): 288-293.
[5]	Muying HUANG,Chu LIU,Jiaman LIU,Zhicong. WANG. Early identification of high⁃risk children who develop systemic adverse reactions related to dust mite allergy subcutaneous immunotherapy [J]. The Journal of Practical Medicine, 2025, 41(19): 3065-3071.
[6]	Lingchun CAO,Fanliang MENG,Xiaoan SHENG. Risk factors and model construction of immune therapy⁃related thyroid dysfunction in non⁃small cell lung cancer [J]. The Journal of Practical Medicine, 2025, 41(17): 2705-2714.
[7]	Caifang GUO,Hong FAN,Ting LUAN,Hui ZHAN,Haifeng WANG,Jiansong WANG. The role and research progress of cytoreductive nephrectomy in metastatic renal cell carcinoma [J]. The Journal of Practical Medicine, 2025, 41(13): 1952-1957.
[8]	Zegong HU,Yan BAI. Research advances in allergen-specific immunotherapy [J]. The Journal of Practical Medicine, 2025, 41(11): 1760-1766.
[9]	Xufeng YU,Meimian HUA,Shuxiong ZENG,Wei HE,Ziwei WANG,Qing CHEN,Chen ZHANG,Yue WANG,Yi WANG,Chuanliang. XU. Clinical efficacy comparison of ileal conduit， flap embedding method， and traditional cutaneous ureterostomy in patients with bladder cancer [J]. The Journal of Practical Medicine, 2025, 41(10): 1517-1524.
[10]	Jiang SHAO,Lin LI,Yansong GUO,Chengyuan SUN,Xichao WEN,Kebin ZHENG,Yanfang SHI. Research progress of CD73/NT5E in glioblastoma [J]. The Journal of Practical Medicine, 2024, 40(3): 428-431.
[11]	Zhaochen SUN,Junyan JIANG,Yitian. CHEN. Advancements in CAR⁃T cell research for the treatment of colorectal cancer [J]. The Journal of Practical Medicine, 2024, 40(18): 2640-2646.
[12]	Ziqi DING,Qian. ZHANG. Research progress in T cell exhaustion and its relationship with respiratory diseases [J]. The Journal of Practical Medicine, 2024, 40(13): 1895-1900.
[13]	Yawei ZHANG,Hongjin SHI,Shi FU,Jiansong WANG,Haifeng WANG. Research progress in biological role of TIGIT and its application in bladder cancer [J]. The Journal of Practical Medicine, 2024, 40(12): 1762-1766.
[14]	Xizhi WEN,Xiaoshi. ZHANG. Immunotherapy based on neoantigen： A personalized treatment strategy for melanoma [J]. The Journal of Practical Medicine, 2024, 40(10): 1331-1337.
[15]	WU Kaiyi, LÜ Xuedong, HE Haiyan, CHEN Jinliang. . Progress in the application of cryoablation combined with immunotherapy in the treatment of NSCLC [J]. The Journal of Practical Medicine, 2023, 39(8): 1058-1062.